Annex 1 is part of the EU GMP guidelines. The revised EU Annex 1 came into effect in August 2023. It defines requirements for the manufacturing of sterile medicinal products with the goal of minimizing contamination risks and ensuring maximum patient safety. A Contamination Control Strategy (CCS) serves as the foundation for all processes, aiming to identify and mitigate potential risks. Cleanroom classification, barrier technologies such as isolators and RABS, and validated sterilization methods are essential to achieving compliance. Continuous environmental monitoring ensures sterility. Annex 1 applies to all manufacturers of sterile medicinal products in the EU, as well as exporters to the EU.
Talk to an expert Challenges and possible solutionsRegulation for the manufacture of sterile medicinal products
Expansion from originally 16 to now 58 pages
Preventing product contamination
Annex 1 defines the strict standards for the manufacture of sterile medicinal products – and with Optima as your partner, you benefit from decades of expertise and state-of-the-art technology to help you meet the highest quality requirements.
We will be happy to send you the white paper on Annex 1. You will receive an e-mail with a download link.
Would you like to optimize your processes in compliance with Annex 1 and learn more about our expertise? We are happy to share our knowledge with you. Download our free whitepaper to gain valuable insights into our solutions and real-world experience.
Why OPTIMA?
Tailored Annex 1 solutions and support from concept to operation and beyond: With extensive practical experience, innovative technologies, and a holistic approach, we help you optimize your production processes—individually, efficiently, and with a focus on the bigger picture. For maximum safety in the manufacturing of your pharmaceutical products.
Your question has not been answered? Please write to us.
Ask a question